242 related articles for article (PubMed ID: 21347516)
1. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma.
Fujimoto K; Kawaguchi T; Nakashima O; Ono J; Ohta S; Kawaguchi A; Tonan T; Ohshima K; Yano H; Hayabuchi N; Izuhara K; Sata M
Oncol Rep; 2011 May; 25(5):1211-6. PubMed ID: 21347516
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
3. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
Riener MO; Fritzsche FR; Soll C; Pestalozzi BC; Probst-Hensch N; Clavien PA; Jochum W; Soltermann A; Moch H; Kristiansen G
Histopathology; 2010 Apr; 56(5):600-6. PubMed ID: 20459570
[TBL] [Abstract][Full Text] [Related]
4. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
5. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
6. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Tao LY; Cai L; He XD; Liu W; Qu Q
Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686
[TBL] [Abstract][Full Text] [Related]
8. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
10. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
Huo TI; Hsia CY; Chu CJ; Huang YH; Lui WY; Wu JC; Lee PC; Chi CW; Lee SD
J Surg Oncol; 2007 Jun; 95(8):645-51. PubMed ID: 17530668
[TBL] [Abstract][Full Text] [Related]
11. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
14. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
15. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
[TBL] [Abstract][Full Text] [Related]
16. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
18. Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma.
Kongtawelert P; Tangkijvanich P; Ong-Chai S; Poovorawan Y
World J Gastroenterol; 2003 Oct; 9(10):2178-81. PubMed ID: 14562373
[TBL] [Abstract][Full Text] [Related]
19. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
